Article
Emerging landscape of KRAS inhibitors in cancer treatment.
Cancer cell - 9 Mar 2026
Riedl Jakob M, Matsubara Hiroyuki, McNeil Reid, Patel Parasvi S, Fece de la Cruz Ferran, Gulhan Doga C, Corcoran Ryan B
Abstract excerpt
Alterations in KRAS, NRAS, and HRAS occur in roughly 20% of patients with cancer, making RAS one of the most intensively studied oncogenic targets. The discovery of mutant-selective KRASG12C inhibitors has provided a proof-of-concept for RAS-directed therapies, heralding a new era in the treatment of RAS-driven cancers. Yet, the efficacy of first-generation KRASG12C inhibitors is limited by the rapid emergence of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.